Search

Your search keyword '"Levesque, B. G."' showing total 22 results
Start Over Author "Levesque, B. G."
22 results on '"Levesque, B. G."'

10. DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis

Author

Sandborn, W, primary, Ding, Z, additional, Osterhout, R, additional, Feagan, B, additional, Danese, S, additional, Jucov, A, additional, Bhandari, B R, additional, Raghupathi, K, additional, Olson, A, additional, Van Biene, C, additional, Ford, J, additional, Aranda, R, additional, Levesque, B G, additional, and Bruey, J M, additional

Published
2021
Full Text
View/download PDF

12. P544 Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study

Author

Feagan, B G, primary, Sandborn, W J, additional, D'Haens, G, additional, Pai, R K, additional, Hanauer, S B, additional, Wolf, D C, additional, Vermeire, S, additional, Ghosh, S, additional, Levesque, B G, additional, Shan, K, additional, Aranda, R, additional, Liu, W J, additional, and Olson, A, additional

Published
2018
Full Text
View/download PDF

13. The development of a magnetic resonance imaging index for fistulising Crohn's disease

Author

Samaan, M. A., primary, Puylaert, C. A. J., additional, Levesque, B. G., additional, Zou, G. Y., additional, Stitt, L., additional, Taylor, S. A., additional, Shackelton, L. M., additional, Vandervoort, M. K., additional, Khanna, R., additional, Santillan, C., additional, Rimola, J., additional, Hindryckx, P., additional, Nio, C. Y., additional, Sandborn, W. J., additional, D'Haens, G., additional, Feagan, B. G., additional, Jairath, V., additional, and Stoker, J., additional

Published
2017
Full Text
View/download PDF

14. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease

Author

Jairath, V., primary, Zou, G., additional, Parker, C. E., additional, MacDonald, J. K., additional, Mosli, M. H., additional, AlAmeel, T., additional, Al Beshir, M., additional, AlMadi, M., additional, Al-Taweel, T., additional, Atkinson, N. S. S., additional, Biswas, S., additional, Chapman, T. P., additional, Dulai, P. S., additional, Glaire, M. A., additional, Hoekman, D., additional, Kherad, O., additional, Koutsoumpas, A., additional, Minas, E., additional, Restellini, S., additional, Samaan, M. A., additional, Khanna, R., additional, Levesque, B. G., additional, D'Haens, G., additional, Sandborn, W. J., additional, and Feagan, B. G., additional

Published
2017
Full Text
View/download PDF

16. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis

Author

Sandborn, W. J., primary, Bhandari, B. R., additional, Fogel, R., additional, Onken, J., additional, Yen, E., additional, Zhao, X., additional, Jiang, Z., additional, Ge, D., additional, Xin, Y., additional, Ye, Z., additional, French, D., additional, Silverman, J. A., additional, Kanwar, B., additional, Subramanian, G. M., additional, McHutchison, J. G., additional, Lee, S. D., additional, Shackelton, L. M., additional, Pai, R. K., additional, Levesque, B. G., additional, and Feagan, B. G., additional

Published
2016
Full Text
View/download PDF

22. HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment.

Author

Pugatch DL, Levesque BG, Lally MA, Reinert SE, Filippone WJ, Combs CM, Flanigan TP, and Brown LK

Subjects
Adolescent, Adult, Feasibility Studies, Female, HIV Infections transmission, HIV-1 immunology, Humans, Male, Risk-Taking, Substance Abuse Treatment Centers, Surveys and Questionnaires, HIV Antibodies blood, HIV Infections diagnosis, Patient Acceptance of Health Care, Substance Abuse, Intravenous complications
Abstract

Objectives: To examine the feasibility and acceptance of HIV testing among youth in acute substance abuse treatment., Methods: Youth, aged 18 to 25 years old, in state-funded inpatient detoxification completed a confidential demographic/risk behavior questionnaire, and were offered a choice of no testing, serum-based testing, or oral fluid (Orasure, Epitope, Inc., Beaverton, OR, U.S.A.) HIV testing., Results: In all, 74% of 204 participants accepted HIV testing. In a multivariate model, female gender (odds ratio [OR], 0.32; 95% confidence interval [CI] 0.14-0.74) and having been recently tested (OR, 0.11; 95% CI, 0.05-0.26) were independently associated with refusing testing. Recent sexual activity (OR, 5.4; 95% CI, 1.5-20.4), recent use of methamphetamines (speed) or a combination of cocaine and heroin (speedball) (OR, 3.8; 95% CI, 1.6-9.0), and a recent perceived risk for HIV (OR, 4.6; 95% CI, 1.9-10.9) were independently associated with test acceptance. Thus, 150 of 150 (100%) chose the Orasure test. Overall, 64.6% (97 of 150) of those tested received their results, but among participants requiring a follow-up appointment to learn test results, only 9.2% (8 of 87) returned., Conclusions: HIV testing is feasible and acceptable in this population. All patients preferred Orasure testing to a serum enzyme-linked immunosorbent assay (ELISA). Most youth tested in detoxification will only learn their results if they are provided during treatment. Rapid HIV testing with same-day results could improve follow-up rates.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results